Celecoxib Inhibits Growth of Tumors in a Syngeneic Rat Liver Metastases Model for Colorectal Cancer

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2008 Feb 6

PMID 18247029

Citations 4

Authors

Pieter de Heer

Maro H Sandel

Gunther Guertens

Gert De Boeck

Margaretha M Koudijs

J Fred Nagelkerke

Jan M C Junggeburt

Ernst A De Bruijn

Cornelis J H van de Velde

Peter J K Kuppen

Affiliations

Soon will be listed here.

Abstract

Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce the risk of colorectal cancer in cyclooxygenase-2 (COX-2) overexpressing colorectal cancers. The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal cancer liver metastases in a syngeneic rat model, CC531.

Materials And Methods: The effects of celecoxib on cell viability in vitro were evaluated by treatment of CC531 tumor cell cultures with celecoxib. In vivo, Wag/Rij rats were inoculated with CC531 tumor cells at two sites in the liver and treated with celecoxib starting one week before, or directly after tumor inoculation. Control rats were inoculated without treatment. Three weeks after tumor inoculation rats were sacrificed. Tumor size, immune cell infiltration, caspase-3 activity, PGE(2) and celecoxib levels were determined.

Results: CC531 tumors did not show COX-2 expression. Tumor growth was significantly inhibited by celecoxib treatment in a dose dependent manner. Immune cell infiltration was decreased after celecoxib treatment, indicating that the immune system was not involved in preventing tumor growth. Tumor caspase-3 levels were only significantly increased if treatment was started before tumor inoculation. Celecoxib serum concentration starting at 0.84 microg/ml significantly inhibited the outgrowth of CC531 liver tumors. In contrast, in vitro concentrations of celecoxib of at least 12 microg/ml were needed to affect tumor cell viability.

Conclusion: These results suggest that the inhibitory effects of celecoxib on tumor growth are not by direct cytotoxicity, but by creating an unfavorable environment for tumor growth.

Citing Articles

The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.

Muller C, Tufa D, Chatterjee D, Muhlradt P, Schmidt R, Jacobs R Cancer Immunol Immunother. 2015; 64(9):1175-84.

PMID: 26036909 PMC: 11028474. DOI: 10.1007/s00262-015-1723-3.

Inhibition of bladder tumor growth by chitooligosaccharides in an experimental carcinogenesis model.

Fernandes J, Sereno J, Garrido P, Parada B, Cunha M, Reis F Mar Drugs. 2013; 10(12):2661-75.

PMID: 23342389 PMC: 3528117. DOI: 10.3390/md10122661.

Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.

Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stockel A, Avril S Breast Cancer Res. 2012; 14(1):R30.

PMID: 22333315 PMC: 3496148. DOI: 10.1186/bcr3115.

Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice.

Pantaleo M, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G Br J Cancer. 2008; 99(10):1729-34.

PMID: 18827815 PMC: 2584956. DOI: 10.1038/sj.bjc.6604681.

References

van Duijnhoven F, Tollenaar R, Terpstra O, Kuppen P . Locoregional therapies of liver metastases in a rat CC531 coloncarcinoma model results in increased resistance to tumour rechallenge. Clin Exp Metastasis. 2005; 22(3):247-53. DOI: 10.1007/s10585-005-8479-7. View

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

Slattery M, Samowitz W, Hoffman M, Ma K, Levin T, Neuhausen S . Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004; 13(4):538-45. View

Yao M, Kargman S, Lam E, Kelly C, Zheng Y, Luk P . Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 2003; 63(3):586-92. View

Buskens C, Sivula A, van Rees B, Haglund C, Offerhaus G, van Lanschot J . Comparison of cyclooxygenase 2 expression in adenocarcinomas of the gastric cardia and distal oesophagus. Gut. 2003; 52(12):1678-83. PMC: 1773905. DOI: 10.1136/gut.52.12.1678. View

Reddy B, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S . Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000; 60(2):293-7. View

Jonges L, Nagelkerke J, Ensink N, van der Velde E, Tollenaar R, Fleuren G . Caspase-3 activity as a prognostic factor in colorectal carcinoma. Lab Invest. 2001; 81(5):681-8. DOI: 10.1038/labinvest.3780277. View

Guirguis M, Sattari S, Jamali F . Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. J Pharm Pharm Sci. 2001; 4(1):1-6. View

Hanif R, Pittas A, Feng Y, Koutsos M, Qiao L, Staiano-Coico L . Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol. 1996; 52(2):237-45. DOI: 10.1016/0006-2952(96)00181-5. View

10.

Geboes K, Dalle I . Influence of treatment on morphological features of mucosal inflammation. Gut. 2002; 50 Suppl 3:III37-42. PMC: 1867680. DOI: 10.1136/gut.50.suppl_3.iii37. View

11.

Tuynman J, Peppelenbosch M, Richel D . COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol. 2004; 52(2):81-101. DOI: 10.1016/j.critrevonc.2004.08.004. View

12.

Hagenaars M, Ensink N, Basse P, Hokland M, Nannmark U, Eggermont A . The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy?. Clin Exp Metastasis. 2001; 18(2):189-96. DOI: 10.1023/a:1006774602360. View

13.

Rocca B, FitzGerald G . Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol. 2002; 2(5):603-30. DOI: 10.1016/s1567-5769(01)00204-1. View

14.

CHAMBERS W, Vujanovic N, DeLeo A, Olszowy M, Herberman R, Hiserodt J . Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med. 1989; 169(4):1373-89. PMC: 2189246. DOI: 10.1084/jem.169.4.1373. View

15.

Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J . Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol. 1999; 164(1):361-70. DOI: 10.4049/jimmunol.164.1.361. View

16.

Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois R . Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998; 93(5):705-16. DOI: 10.1016/s0092-8674(00)81433-6. View

17.

Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F . Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum. 2005; 52(12):3898-909. DOI: 10.1002/art.21426. View

18.

Tuynman J, Buskens C, Kemper K, Ten Kate F, Offerhaus G, Richel D . Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann Surg. 2005; 242(6):840-9, discussion 849-50. PMC: 1409886. DOI: 10.1097/01.sla.0000189546.77520.ef. View

19.

Chen W, Wei S, Liu J, Hsiao M, Yang W . Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer. 2001; 91(6):894-9. DOI: 10.1002/1097-0215(200102)9999:9999<894::aid-ijc1146>3.0.co;2-#. View

20.

Raz A . Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol. 2002; 63(3):343-7. DOI: 10.1016/s0006-2952(01)00857-7. View